Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.60 |
| ▸ | TP53 | P04637 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | MGAM | O43451 | 1/20 | 0.51 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16420854 | 0.92 | MAPT (0.64) | MAPTTP53LMNAMGAMAMY1A | |
| SCHEMBL15997304 | 0.89 | MAPT (0.63) | MAPTTP53LMNAMGAMAMY1A | |
| SCHEMBL15987693 | 0.86 | MAPT (0.67) | MAPTTP53LMNAMGAMAMY1A | |
| SCHEMBL15987544 | 0.86 | MAPT (0.64) | MAPTTP53LMNAMGAMAMY1A | |
| SCHEMBL266049 | 0.85 | KMT2A (0.54) | MAPTTP53AMY1APOLBMEN1 | |
| SCHEMBL16420841 | 0.85 | MAPT (0.64) | MAPTTP53LMNAMGAMAMY1A | |
| SCHEMBL15997224 | 0.85 | MAPT (0.64) | MAPTTP53LMNAMGAMAMY1A | |
| SCHEMBL15997209 | 0.85 | MAPT (0.64) | MAPTTP53LMNAMGAMAMY1A | |
| SCHEMBL15997286 | 0.85 | MAPT (0.64) | MAPTTP53LMNAMGAMAMY1A | |
| SCHEMBL16420852 | 0.85 | MAPT (0.64) | MAPTTP53LMNAMGAMAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062032-B2 | Aminoalkyl-substituted N-thienylbenzamide derivative | ASTELLAS PHARMA INC. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062032-B2 | Aminoalkyl-substituted N-thienylbenzamide derivative | ASTELLAS PHARMA INC. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | SLC34A2, SLC10A2, ALPI | MAPT 1901/4885TP53 3228/4885LMNA 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.